Enhertu and Kidney Effects
Enhertu does not cause direct kidney toxicity and does not require dose adjustment for mild-to-moderate renal impairment (creatinine clearance ≥30 mL/min), but patients with moderate renal impairment require more frequent monitoring due to a higher incidence of interstitial lung disease/pneumonitis. 1
Direct Renal Effects
Enhertu (trastuzumab deruxtecan) is not nephrotoxic in the traditional sense. The FDA label explicitly states:
- No dose adjustment required for mild renal impairment (CrCl ≥60 and <90 mL/min)
- No dose adjustment required for moderate renal impairment (CrCl ≥30 and <60 mL/min) 1
However, there is an important caveat: patients with moderate renal impairment have a higher incidence of Grade 1 and 2 interstitial lung disease/pneumonitis and should be monitored more frequently 1. This is not direct kidney toxicity but rather an increased risk of Enhertu's most serious adverse effect in the setting of reduced kidney function.
Severe Renal Impairment
For patients with severe renal impairment (CrCl <30 mL/min), the recommended dosage has not been established, meaning there is insufficient data to guide dosing in this population 1.
Mechanism and Context
Enhertu is an antibody-drug conjugate (ADC) consisting of a HER2-directed antibody linked to a topoisomerase inhibitor payload (DXd). As an intact IgG-based macromolecule, it has limited glomerular filtration under normal conditions 2. The small-molecule payload may undergo some renal processing, but this does not translate to clinically significant nephrotoxicity in the majority of patients.
Recent emerging data suggests that some ADCs, including trastuzumab deruxtecan, may cause proximal tubular injury patterns (Fanconi-like syndrome) in rare cases 2. This represents a hypothesis-generating signal rather than established toxicity, but clinicians should be aware of potential electrolyte disturbances (hypokalemia, hypophosphatemia, glycosuria) that could indicate proximal tubular dysfunction.
Practical Management for Your Patient (Creatinine ~2 mg/dL)
With a serum creatinine of approximately 2 mg/dL, your patient likely has moderate renal impairment (estimated CrCl 30-60 mL/min, depending on age, weight, and sex):
- Continue standard Enhertu dosing (5.4 mg/kg every 3 weeks for most indications)
- Increase monitoring frequency for signs/symptoms of ILD/pneumonitis (dyspnea, cough, fever)
- Monitor electrolytes (potassium, phosphate, bicarbonate) and urinalysis periodically to detect rare proximal tubular injury
- Avoid nephrotoxic co-medications (NSAIDs, aminoglycosides) when possible 3
Important Distinctions
Unlike traditional HER2-targeted therapy (trastuzumab), which has been associated with changes in kidney function potentially mediated through cardiac effects 4, Enhertu's renal safety profile is distinct. The general onco-nephrology literature confirms that HER2-targeted agents as a class are not typically nephrotoxic 5, 6, and Enhertu follows this pattern.
The broader context from onco-nephrology guidelines 7 emphasizes that many anticancer drugs cause kidney injury through various mechanisms (acute tubular injury, thrombotic microangiopathy, interstitial nephritis), but antibody-based therapies like Enhertu are not among the high-risk nephrotoxic agents such as platinum compounds, anti-angiogenesis drugs, or immune checkpoint inhibitors.
Key Pitfalls to Avoid
- Do not withhold or reduce Enhertu dosing based solely on moderate renal impairment (CrCl ≥30 mL/min)
- Do not confuse the increased ILD/pneumonitis risk in moderate renal impairment with direct kidney toxicity
- Do not rely on creatinine alone for ongoing monitoring—consider cystatin C if there is concern about pseudo-worsening of kidney function from other medications 8
- Do assess volume status carefully, as dehydration from Enhertu-associated nausea/vomiting could cause prerenal azotemia